Evidence map›Paper›PMID 32138199›Full record

ArticlePathogens (Basel, Switzerland)2020

Specific Substitutions in Region V2 of gp120

Yalcin Pisil, Zafer Yazici, Hisatoshi Shida, Shuzo Matsushita, Tomoyuki Miura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Yalcin PisilLaboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto 615-8530, Japan.
Zafer YaziciDepartment of Virology, Faculty of Veterinary Medicine, 19 Mayis University, Samsun 55270, Turkey.
Hisatoshi ShidaDivision of Molecular Virology, Institute of Immunological Science, Hokkaido University, Hokkaido 060-0808, Japan.
Shuzo MatsushitaCenter for AIDS Research, Kumamoto University, Kumamoto 860-8555, Japan.
Tomoyuki MiuraLaboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto 615-8530, Japan.ORCID 0000-0002-1956-2180
Kyoto University · JPHokkaido University · JPKumamoto University · JPOndokuz Mayıs University · TR

Funding

Japan Agency for Medical Research and Development (AMED) JP18fk0410011, JP18fk0410002, JP18fk0410013Scientific Research (B) from the Japan Society for the Promotion of Science 16H04682
6 · The paper itself

Abstract

A tier 2 SHIV-MK38 strain was obtained after two in vivo passages of tier 1 SHIV-MK1. SHIV-MK38#818, cloned from the MK38 strain, was neutralisation-resistant, like the parental MK38 strain, to SHIV-infected monkey plasma (MP), HIV-1-infected human pooled plasma (HPP), and KD247 monoclonal antibody (mAb) (anti-V3 gp120

Indexed as

AIDSCCR5EnvHIVmutagenesisRhesus macaqueSHIVV2 region

Identifiers

PMID32138199
PMCPMC7157653
OpenAlexW3009568855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.